DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
Filed with ASX · · 3 pages · English
Earlier from Mesoblast
- COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
- MSB Wins Fierce Biotech Innovation Award for Remestemcel-L
- DSMB Recommends Continuation of Phase 3 COVID-19 Trial
- ODAC Votes in Favor of Remestemcel-L for GvHD
- Update on Scheduled FDA Advisory Committee Meeting
Later from Mesoblast
- First Quarter Results Presentation
- Novartis and Mesoblast Remestemcel-L Collaboration
- Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
- Mesoblast Phase 3 Chronic Heart Failure Results
- Trading halt
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast